- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
Patent holdings for IPC class A61K 31/5513
Total number of patents in this class: 1505
10-year publication summary
|
94
|
89
|
103
|
140
|
128
|
119
|
134
|
131
|
100
|
83
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| The Regents of the University of California | 20230 |
38 |
| Bristol-myers Squibb Company | 4848 |
32 |
| Alkermes Pharma Ireland Limited | 260 |
29 |
| Jazz Pharmaceuticals Research UK Limited | 213 |
23 |
| Enanta Pharmaceuticals, Inc. | 433 |
22 |
| Nippon Chemiphar Co., Ltd. | 232 |
22 |
| Neurelis, Inc. | 56 |
20 |
| Ovid Therapeutics Inc | 167 |
16 |
| Boehringer Ingelheim International GmbH | 4648 |
15 |
| GW Research Limited | 195 |
15 |
| Ayala Pharmaceuticals Inc. | 18 |
13 |
| Pfizer Inc. | 3397 |
12 |
| Novartis AG | 10656 |
11 |
| io Therapeutics, Inc. | 120 |
11 |
| Santen Pharmaceutical Co., Ltd. | 599 |
11 |
| Aquestive Therapeutics, Inc. | 181 |
11 |
| Clexio Biosciences Ltd. | 104 |
11 |
| F. Hoffmann-La Roche AG | 7932 |
10 |
| The Johns Hopkins University | 5739 |
10 |
| Dana-Farber Cancer Institute, Inc. | 2615 |
10 |
| Other owners | 1163 |